체외진단(IVD) 검사 건수 (제8판)

The world runs on roughly 150 billion diagnostic tests a year - and that number is climbing faster than the revenue behind it. IVD Test Procedure Volumes, 8th Edition quantifies that divergence with precision, tracking global procedure volumes segment by segment and region by region as the diagnostics industry completes its transition out of the pandemic era. Test demand is rising meaningfully faster than test dollars, and that widening gap between how many procedures the world performs and what those procedures are worth is the central strategic story of this decade. It’s the story IVD Test Procedure Volumes, 8th Edition is built to explain. The report serves as the essential companion to Kalorama Information’s flagship The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 19th Edition (2025–2030).

Where the Volume Is - and Where the Growth Is

Routine testing still carries the load. Clinical chemistry, immunoassays, hematology, coagulation, and microbiology continue to generate the overwhelming majority of the world’s procedure volume, and any credible market model has to start there. But the momentum sits elsewhere: molecular oncology, companion diagnostics, and targeted point-of-care applications are expanding well ahead of the market average. This edition separates the two clearly - thirteen testing categories, procedure counts and product sales, blood glucose included and excluded - so decision-makers can see not just how big a segment is, but which direction it is moving and how much revenue each test actually captures.

From Pandemic Capacity to Precision Demand

The infrastructure built for COVID-19 - PCR capacity, lab automation, respiratory panels, home testing, and a durable acceptance of decentralized diagnostics - has not disappeared; it has been redirected. It now drives testing for influenza, RSV, STIs, tuberculosis, healthcare-associated infections, and emerging pathogens. Meanwhile, next-generation sequencing (NGS) is moving into cancer profiling, inherited disease, reproductive health, and transplant testing, and liquid biopsy is extending genomic analysis into therapy selection and recurrence monitoring.

The Pressures That Will Decide Winners

Volume growth does not guarantee margin growth. Payers increasingly demand evidence that a test changes clinical management rather than simply adding data. Laboratories are absorbing staffing shortages, supply-chain risk, cybersecurity requirements, and the cost of maintaining multiple specialized platforms. Regulation is reshaping availability on both sides of the Atlantic. This report frames key forces not as background noise but as the specific variables that will separate the companies that scale from those that stall.

Built for the Decisions You Actually Make

Drawing on Kalorama’s proprietary, transparent methodology, IVD Test Procedure Volumes, 8th Edition delivers procedure volumes, product sales, and per-procedure cost dynamics across every major segment and across key markets from North America and Western Europe to the highest-opportunity developing regions. For executives sizing a portfolio, strategists choosing where to invest, and marketers positioning against real utilization data rather than headline hype, it answers the question that matters most: not just where the IVD market is going, but where the testing is and what it’s worth.

CHAPTER ONE: EXECUTIVE SUMMARY

ABOUT KALORAMA INFORMATION

OVERVIEW

IVD PROCEDURE VOLUME ESTIMATE AND FORECAST

• Figure 1-1: Global IVD Procedure Volumes, 2025 and 2030 (in millions # volume)

SCOPE & METHODOLOGY

CHAPTER TWO: INTRODUCTION

SCOPE

OVERVIEW

INDUSTRY TRENDS

• Table 2-1: Global IVD Procedural Volume & Product Sales (includes glucose tests), 2025-2030 (in millions # volume; US$ millions)

DEMOGRAPHIC TRENDS

• Global Population and Aging
  • Figure 2-1: Global Fertility Rate vs. Population Size, 1950-2050 (billion)
  • Figure 2-2: Global Population Distribution, 2022
  • Table 2-2: Elderly Support Ratio in Various Countries, 2010 and 2050
• Workforce Reduction
  • Table 2-3: WHO Model List of Essential In Vitro Diagnostics (EDL)

INCREASE IN CHRONIC DISEASES

• Figure 2-3: Leading Causes of Death Globally, 2021* (number of deaths in millions)

PERSONALIZED MEDICINE

HIGH-CONSEQUENCE DISEASE THREATS

• Table 2-4: Selected Companies Marketing Products Addressing High-Consequence Infectious Disease Threats

Tickborne Diseases (TBDs)

Zika

Chagas

Dengue

Ebola

Chikungunya

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Marburg

Mpox

EMERGING AND EMERGED MARKETS

• Table 2-5: Developed/Developing Economies, UN Classification*, 2025
• Figure 2-4: Developed vs. Developing IVD Market Shares, 2025 and Projected 2030 (%)
• Table 2-6: Countries To Watch for IVD Opportunities, by Total Population and Percent Urban, 2025 (population in millions)

CHAPTER THREE: IVD TESTING SEGMENTS

SCOPE

IVD TESTING TRENDS

• Table 3-1: IVD Procedural Volume including Blood Glucose Tests, by Item, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]
• Table 3-2: IVD Procedural Volume including Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]
• Table 3-3: IVD Procedural Volume excluding Blood Glucose Tests, 2025-2030 (millions) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]
• Table 3-4: IVD Procedural Volume excluding Blood Glucose Tests, Share by Item, 2025-2030 (%) [Blood Grouping/Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]

SEGMENT GROWTH PROJECTIONS

• POC Testing
• Clinical Chemistry
• Immunoassays
• Mass Spectrometry (Immuno)
• Molecular Assays
• Hematology
• Coagulation
• Conventional Microbiology
• Blood Grouping/Typing
• Histology/Cytology

SEGMENT PRODUCT SALES

• Table 3-5: IVD Product Sales including Blood Glucose Tests, 2025-2030 (US$ millions) [Blood Grouping/ Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/ Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]
• Figure 3-1: Test Volume Share vs. Sales Share by IVD Item, including Blood Glucose Tests, 2025 (%) [Blood Grouping/ Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/ Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]
• Figure 3-2: Test Volume Share vs. Sales Share by IVD Item, including Blood Glucose Tests, 2030 (%) [Blood Grouping/ Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/ Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]
• Table 3-6: IVD Product Sales excluding Blood Glucose Tests, 2025-2030 (US$ millions) [Blood Grouping/ Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/ Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]
• Figure 3-3: Test Volume Share vs. Sales Share by IVD Item, excluding Blood Glucose Tests, 2025 (%) [Blood Grouping/ Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/ Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]
• Figure 3-4: Test Volume Share vs. Sales Share by IVD Item, excluding Blood Glucose Tests, 2025 (%) [Blood Grouping/ Typing, Clinical Chemistry, Coagulation, Conventional Microbiology, Hematology, Histology/ Cytology, Immunoassays, Mass Spectrometry (Immuno), Mass Spectrometry (Micro), Molecular, POC Professional Tests, POC Self Testing, Other]

CHAPTER FOUR: GLOBAL IVD MARKETS

GENERAL

• Table 4-1: IVD Procedural Volume including Blood Glucose Tests, by Region, 2025-2030 (millions) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Middle East, Mexico, Central, & South America; North America (Canada, United States); Western Europe]
• Table 4-2: IVD Procedural Volume including Blood Glucose Tests, Share by Region, 2025-2030 (%) [Africa; Asia/Pacific (China, Japan, Other Countries & Territories); Eastern Europe; Middle East, Mexico, Central, & South America; North America (Canada, United States); Western Europe]

NORTH AMERICA

• United States
• Canada

MEXICO, CENTRAL, & SOUTH AMERICA

• Brazil
• Mexico
• Other Central & South America
• Argentina
• Chile
• Colombia
• Peru
• Venezuela
• All Other Countries & Territories

WESTERN EUROPE

• France
• Germany
• Italy
• Spain
• United Kingdom
• Other Western Europe
• Austria
• Belgium
• Denmark
• Finland
• Greece
• Ireland
• Norway
• Netherlands
• Portugal
• Sweden
• Switzerland
• All Other Countries & Territories

EASTERN EUROPE

• Russia
• Other Eastern Europe
• Czech Republic
• Hungary
• Poland
• Romania
• Ukraine
• All Other Countries

ASIA/PACIFIC

• China
• Japan
• Other Asian Countries and Territories
• Australia
• Hong Kong
• India
• Indonesia
• Malaysia
• Pakistan
• Philippines
• Singapore
• South Korea
• Taiwan
• Thailand
• Vietnam
• New Zealand
• All Other Countries & Territories

MIDDLE EAST

• Turkey
• Other Middle East
• Iran
• Iraq
• Israel
• Saudi Arabia
• United Arab Emirates
• All Other Countries

AFRICA

• Nigeria
• South Africa
• All Other Countries & Territories

CHAPTER FIVE: POINT-OF-CARE (POC) PROCEDURES

SCOPE

INTRODUCTION

GLOBAL POC PROCEDURE VOLUME BY TEST TYPE

• Table 5-1: Total POC Procedural Volume & Product Sales including blood glucose tests, 2025-2030
• Figure 5-1: POC Procedure Volume and Product Sales Share, by Test Type including blood glucose tests, 2025 and 2030 (%)
• Figure 5-2: POC Revenue per Test, by Test Type including blood glucose tests, 2025 and 2030 (US$)
• Figure 5-3: Regional POC Procedure Volumes including blood glucose tests, 2025
• Table 5-2: Total POC Procedural Volume & Product Sales excluding blood glucose tests, 2025-2030
• Figure 5-4: POC Procedure Volume and Product Sales Share, by Test Type excluding blood glucose tests, 2025 and 2030 (%)
• Figure 5-5: POC Revenue per Test, by Test Type excluding blood glucose tests, 2025 and 2030 (US$)

POC SELF TESTS

• Table 5-3: POC Self-Test Procedural Volume, by Type, 2025-2030 (millions) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose (Continuous), Glucose (Self), H. pylori, HIV, Infectious disease (inc. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]

Traditional Blood Glucose Monitoring Activities

Continuous Blood Glucose Monitoring

Pregnancy and Fertility Testing

Coagulation Testing

Fecal Occult Blood Testing

Drugs of Abuse Testing

Pylori Testing

HIV Testing

Infectious Disease

Cholesterol Testing

POC Urinalysis Testing

Other POC Self-Testing

POC SELF-TESTING PRODUCT SALES

• Table 5-4: POC Self-Test Product Sales, by Type, 2025-2030 (US$ millions) [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose (Continuous), Glucose (Self), H. pylori, HIV, Other Infectious Disease (inc. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]

PRICING TRENDS

• Table 5-5: POC Self-Test $ IVD Product Sales Per Procedure, 2025-2030 [Cholesterol, Coagulation, Drugs of Abuse, Fecal Occult Blood, Glucose (Continuous), Glucose (Self), H. pylori, HIV, Other Infectious Disease (inc. COVID-19), Pregnancy, Urinalysis, Other (TSH, Allergy, Autoimmune, etc.)]

POC PROFESSIONAL TESTING

• Table 5-6: POC Professional Procedural Volume, by Type, 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fecal Occult Blood, Fertility, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]

POC Professional Blood Glucose Testing Procedures

POC Professional Critical Care Testing

POC Fertility Testing

POC Professional Infectious Disease Testing

POC Professional Cardiac Marker Testing

POC Professional Cholesterol/Lipid Testing

POC Professional Coagulation Testing

POC Professional HbA1C Testing

POC Professional Hematology Testing

POC Professional Fecal Occult Blood Screening

POC Professional Drugs of Abuse Testing

POC Professional Urinalysis Testing

Other POC Professional Testing

POC IVD PRODUCT SALES

• Table 5-7: POC Professional IVD Product Sales, by Type, 2025-2030 (US$ millions) [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fertility, Fecal Occult Blood, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]

PRICING TRENDS

• Table 5-8: POC Professional $ IVD Product Sales Per Procedure, by Type, 2025-2030 [Cardiac Markers, Cholesterol, Coagulation, Critical Care POC, Drugs of Abuse, Fertility, Fecal Occult Blood, Glucose, HbA1c POC, Hematology, Infectious Diseases, Urine, Others]

CHAPTER SIX: CLINICAL CHEMISTRY PROCEDURES

SCOPE

INTRODUCTION

• Table 6-1: Clinical Chemistry Procedural Volume, by Type, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]
• Figure 6-1: Regional Clinical Chemistry Procedure Volumes, 2025

TYPES OF TESTS

General Chemistry

• Enzymes
• Glucose
• Lipids
• Proteins

Other Compounds

Blood Gases & Electrolytes

Urinalysis

GLOBAL SALES OF CLINICAL CHEMISTRY PRODUCTS

• Table 6-2: Clinical Chemistry Product Sales, by Type, 2025-2030 (US$ millions) [Blood Gas Analysis, General Chemistry, Urinalysis]

PRICING TRENDS

• Table 6-3: Clinical Chemistry $ IVD Product Sales Per Procedure, 2025-2030 [Blood Gas Analysis, General Chemistry, Urinalysis]

CHAPTER SEVEN: IMMUNOASSAY PROCEDURES

SCOPE

INTRODUCTION

TECHNOLOGIES

LABELING TECHNIQUES

Enzyme and Chemiluminescent Immunoassays

Radioimmunoassays

• Table 7-1: Immunoassay Procedural Volume, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spec, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]
• Figure 7-1: Regional Immunoassay Procedure Volumes, 2025

TESTING PROCEDURES & PRODUCT SALES

• Table 7-2: Immunoassay Product Sales, by Type, 2025-2030 (US$ millions) [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spec, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]

Cardiac Markers

Tumor Markers

Autoimmune Conditions

Allergy Conditions

Thyroid Conditions

Proteins

• Alzheimer’s Disease

Anemia

Fertility Testing

Therapeutic Drug Monitoring

Vitamin D

Diabetes/HbA1c

Drugs of Abuse

Infectious Diseases

• Table 7-3: Immunoassay Infectious Disease Procedural Volume, by Type, 2025-2030 [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]
• Table 7-4: Immunoassay Infectious Disease Product Sales, by Type, 2025-2030 (US$ millions) [HAI, Hepatitis, HIV, Resp, STD, ToRCH, Other]

INSTRUMENTS

PRICING TRENDS

• Table 7-5: Immunoassay $ Product Sales Per Procedure, by Type, 2025-2030 [Allergy, Anemia, Autoimmune, Cardiac Markers, Diabetes/HbA1c, Fertility, Infectious Disease, Mass Spec, Proteins, Therapeutic Drugs, Thyroid, Tox/Drug of Abuse, Tumor Markers, Vitamin D, Others]

CHAPTER EIGHT: MOLECULAR TESTING PROCEDURES

INTRODUCTION

• Table 8-1: Molecular Assay Procedural Volume, by Type, 2025-2030 [Molecular Assays - Oncology, Molecular Blood Bank, Molecular Histology - Non Cancer, Molecular Histology - Cancer, Molecular HPV, Molecular Infectious Disease, Molecular Inherited Diseases, Molecular Other, Molecular PT/INR (Thrombophilia SNP Tests), Molecular Transplant Testing (HLA) Tissue Typing, Prenatal]
• Figure 8-1: Regional Molecular Assay Procedure Volumes, 2025

TYPES OF TESTS

Testing Technologies

Infectious Diseases

• Table 8-2: Molecular Assay Infectious Disease Procedural Volume, by Type, 2025-2030 [COVID, GC, HAI, Hepatitis, HIV, Respiratory, TB, Other]

Blood Screening

Cancer

Transplant Matching

Thrombophilia SNPs

Inherited Diseases

Other Molecular Tests

Prenatal

GLOBAL SALES OF MOLECULAR IVD PRODUCTS

• Table 8-3: Molecular Assay Product Sales, by Type, 2025-2030 (US$ millions) [Molecular Assays - Oncology, Molecular Blood Bank, Molecular Histology - Non Cancer, Molecular Histology - Cancer, Molecular HPV, Molecular Infectious Disease, Molecular Inherited Diseases, Molecular Other, Molecular PT/INR (Thrombophilia SNP Tests), Molecular Transplant Testing (HLA) Tissue Typing, Prenatal]
• Table 8-4: Molecular Assay Infectious Disease Product Sales, by Type, 2025-2030 (US$ millions) [COVID-19, GC/Chlamydia, HAI, Hepatitis, HIV, Mycobacteria/TB, Respiratory - Non-COVID, Other]

PRICING TRENDS

• Table 8-5: Molecular Assays $ Product Sales Per Procedure, by Type, 2025-2030 [Molecular Assays - Oncology, Molecular Blood Bank, Molecular Histology - Cancer, Molecular Histology - Non Cancer, Molecular HPV, Molecular Inherited Diseases, Molecular Infectious Disease, Molecular Other, Molecular PT/INR (Thrombophilia SNP Tests), Molecular Transplant Testing (HLA) Tissue Typing, Prenatal]

CHAPTER NINE: LABORATORY-BASED HEMATOLOGY PROCEDURES

SCOPE

INTRODUCTION

• Table 9-1: Laboratory-Based Hematology Procedural Volume, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]
• Figure 9-1: Regional Laboratory-Based Hematology Procedure Volumes, 2025

TYPES OF TESTS

GLOBAL SALES OF HEMATOLOGY PRODUCTS

• Table 9-2: Laboratory-Based Hematology Product Sales, by Type, 2025-2030 (US$ millions) [Complete Blood Count, Other Hematology Tests]

PRICING TRENDS

• Table 9-3: Hematology $ Product Sales Per Procedure, by Type, 2025-2030 [Complete Blood Count, Other Hematology Tests]

CHAPTER TEN: COAGULATION TESTING PROCEDURES

INTRODUCTION

• Table 10-1: Coagulation Procedural Volume, 2025-2030 [D-dimer, PT/INR]
• Figure 10-1: US/ROW Coagulation Procedure Volumes, 2025

TYPES OF TESTS

GLOBAL SALES OF COAGULATION PRODUCTS

• Table 10-2: Coagulation Product Sales, 2025-2030 (US$ millions) [D-dimer, PT/INR]

PRICING TRENDS

• Table 10-3: Coagulation $ Product Sales Per Procedure, 2025-2030 [D-dimer, PT/INR]

CHAPTER ELEVEN: MICROBIOLOGY PROCEDURES

SCOPE

INTRODUCTION

• Table 11-1: Conventional Microbiology Procedural Volume, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]
• Figure 11-1: US/ROW Microbiology Procedure Volumes, 2025

TYPES OF TESTS

• ID/AST Automated Panels & Reagents
• Manual Panels & Reagents
• Blood Culture
• Chromogenic Media
• Rapid Microbiological Tests
• Mass Spectrometry

GLOBAL SALES OF CONVENTIONAL IVD MICROBIOLOGY PRODUCTS

ID/AST Panels & Reagents

Blood Culture

Chromogenic Media

Rapid Microbiological Tests

Mass Spectrometry

• Table 11-2: Conventional Microbiology Product Sales, by Type, 2025-2030 (US$ millions) [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry, Rapid Microbiology]

PRICING TRENDS

• Table 11-3: Conventional Microbiology $ Product Sales Per Procedure, by Type, 2025-2030 [Blood Culture, Chromogenic Media, ID/AST Automated, ID/AST Panels, Mass Spectrometry (micro), Rapid Microbiology]

CHAPTER TWELVE: BLOOD GROUPING/TYPING PROCEDURES

INTRODUCTION

• Table 12-1: Blood Grouping/Typing Procedure Volumes, 2025-2030
• Figure 12-1: Regional Blood Grouping/Typing Procedure Volumes, 2025

TYPES OF TESTS

BLOOD GROUPING/TYPING PRODUCT SALES

• Table 12-2: Blood Grouping/Typing Product Sales, 2025-2030 (US$ millions)

PRICING TRENDS

• Table 12-3: Blood Grouping/Matching $ Product Sales Per Procedure, 2025-2030

CHAPTER THIRTEEN: HISTOLOGY/CYTOLOGY PROCEDURES

SCOPE

INTRODUCTION

• Table 13-1: Histology/Cytology Procedural Volume, by Type, 2025-2030 [Circulating Tumor Cells (CTCs), Flow Cytometry, Immunohistochemistry, In Situ Hybridization (ISH), Pap Tests, Traditional non-Pap Stains]
• Figure 13-1: Regional Histology/Cytology Procedure Volumes, 2025

TYPES OF TESTS

• Immunohistochemistry Tests
• In Situ Hybridization (ISH) Tests
• Pap Tests
• Traditional Non-Pap Stains
• Circulating Tumor Cells
• Flow Cytometry

HISTOLOGY/CYTOLOGY IVD PRODUCT SALES

• Table 13-2: Histology/Cytology Product Sales, by Type, 2025-2030 (US$ millions) [Circulating Tumor Cells (CTCs), Flow Cytometry, Immunohistochemistry, In Situ Hybridization (ISH), Pap Tests, Traditional non-Pap Stains]

PRICING TRENDS

• Table 13-3: Histology/Cytology $ Product Sales Per Procedure, by Type, 2025-2030 [Circulating Tumor Cells (CTCs), Flow Cytometry, Immunohistochemistry, In Situ Hybridization (ISH), Pap Tests, Traditional non-Pap Stains]